MA46878A - Composés de benzodiazolium en tant qu'inhibiteurs d'enac - Google Patents

Composés de benzodiazolium en tant qu'inhibiteurs d'enac

Info

Publication number
MA46878A
MA46878A MA046878A MA46878A MA46878A MA 46878 A MA46878 A MA 46878A MA 046878 A MA046878 A MA 046878A MA 46878 A MA46878 A MA 46878A MA 46878 A MA46878 A MA 46878A
Authority
MA
Morocco
Prior art keywords
benzodiazolium
compounds
enac inhibitors
enac
inhibitors
Prior art date
Application number
MA046878A
Other languages
English (en)
French (fr)
Inventor
Jonathan David Hargrave
Duncan Alexander Hay
Clive Mccarthy
Thomas Beauregard Schofield
Naomi Went
Original Assignee
Enterprise Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterprise Therapeutics Ltd filed Critical Enterprise Therapeutics Ltd
Publication of MA46878A publication Critical patent/MA46878A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA046878A 2016-11-22 2017-11-22 Composés de benzodiazolium en tant qu'inhibiteurs d'enac MA46878A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1619694.1A GB201619694D0 (en) 2016-11-22 2016-11-22 Compounds

Publications (1)

Publication Number Publication Date
MA46878A true MA46878A (fr) 2019-10-02

Family

ID=57993838

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046878A MA46878A (fr) 2016-11-22 2017-11-22 Composés de benzodiazolium en tant qu'inhibiteurs d'enac

Country Status (20)

Country Link
US (4) US10941149B2 (https=)
EP (1) EP3544981B1 (https=)
JP (1) JP6980014B2 (https=)
KR (1) KR102517273B1 (https=)
CN (1) CN110214141B (https=)
AU (1) AU2017364308B2 (https=)
CA (1) CA3043132A1 (https=)
DK (1) DK3544981T3 (https=)
EA (1) EA039607B1 (https=)
ES (1) ES2890226T3 (https=)
GB (1) GB201619694D0 (https=)
HU (1) HUE055692T2 (https=)
IL (1) IL266745B (https=)
MA (1) MA46878A (https=)
MX (1) MX389496B (https=)
PL (1) PL3544981T3 (https=)
PT (1) PT3544981T (https=)
TW (1) TWI756305B (https=)
WO (1) WO2018096325A1 (https=)
ZA (1) ZA201902710B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) * 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) * 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
PH12021553110A1 (en) 2019-06-12 2022-08-01 Tmem16A Ltd Compounds for treating respiratory disease
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
EP4259607A1 (en) 2020-12-11 2023-10-18 Tmem16A Limited Benzimidazole derivatives for treating respiratory disease
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
GB202406247D0 (en) 2024-05-03 2024-06-19 Enterprise Therapeutics Ltd Compounds and pharmaceutical compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US7375107B2 (en) 2003-08-18 2008-05-20 Parion Sciences, Inc. Alaphatic pyrazinoylguanidine sodium channel blockers
JP2007502829A (ja) 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 環状ピラジノイルグアニジンナトリウムチャネルブロッカー
ES2432529T3 (es) 2003-08-18 2013-12-04 Parion Sciences, Inc. Bloqueadores del canal de sodio de pirazinoilguanidina rematada
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
EP1678145A2 (en) * 2003-10-28 2006-07-12 Vertex Pharmaceuticals Incorporated Benzimidazoles useful as modulators of ion channels
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
ES2400287T3 (es) * 2005-03-14 2013-04-08 High Point Pharmaceuticals, Llc Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US8288391B2 (en) 2007-04-03 2012-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use as taste modulators
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
MX2010006421A (es) 2007-12-10 2010-06-25 Novartis Ag Compuestos organicos.
ES2485642T3 (es) 2008-02-26 2014-08-14 Parion Sciences, Inc. Bloqueantes poli-aromáticos de los canales de sodio
CA2723938A1 (en) 2008-05-13 2009-11-19 Novartis Ag 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases
JP2011522860A (ja) 2008-06-10 2011-08-04 ノバルティス アーゲー 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
TW201204353A (en) * 2010-06-08 2012-02-01 Vertex Pharma Formulations of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
KR102006612B1 (ko) 2011-11-02 2019-08-02 베링거 인겔하임 인터내셔날 게엠베하 헤테로사이클릭 화합물, 상기 화합물을 포함하는 약제, 이의 용도, 및 이의 제조 방법
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
HUE039734T2 (hu) 2012-05-29 2019-01-28 Parion Sciences Inc Nátriumcsatorna-blokkoló aktivitású, dendrimerszerû amino-amid-származékok száraz szem és más nyálkahártya-megbetegedések kezelésére
US8841309B2 (en) 2012-09-24 2014-09-23 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
EP2991981B1 (en) 2013-04-30 2017-03-01 Boehringer Ingelheim International GmbH Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
AU2014284268A1 (en) 2013-07-02 2016-01-07 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
EP3019492B1 (en) 2013-07-08 2017-09-06 Boehringer Ingelheim International GmbH Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
JP6461134B2 (ja) 2013-07-15 2019-01-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ベンゾイミダゾリウム化合物
WO2015007516A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel 5-substituted benzimidazolium compounds
WO2015018754A1 (en) 2013-08-08 2015-02-12 Boehringer Ingelheim International Gmbh Novel pyrazine amide compounds
WO2016113169A1 (en) 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Tetra- and pentasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases
EP3245199B1 (en) * 2015-01-12 2020-01-01 Boehringer Ingelheim International GmbH Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
JP6847838B2 (ja) 2015-01-12 2021-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 上皮ナトリウムチャネル阻害剤としての2−(ピラジン−2−イルカルボニルアミノメチル)ベンズイミダゾリウム化合物
US9932324B2 (en) 2015-01-12 2018-04-03 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
MX370598B (es) 2015-08-20 2019-12-18 Boehringer Ingelheim Int Fenoxiacetamidas apareadas novedosas.
EA201890532A1 (ru) 2015-08-20 2018-09-28 Бёрингер Ингельхайм Интернациональ Гмбх Новые аннелированные бензамиды
GB201610854D0 (en) * 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
AU2017364308B2 (en) 2021-03-11
MX389496B (es) 2025-03-20
IL266745B (en) 2021-12-01
WO2018096325A1 (en) 2018-05-31
EP3544981A1 (en) 2019-10-02
KR20190084076A (ko) 2019-07-15
NZ753048A (en) 2024-09-27
EP3544981B1 (en) 2021-06-23
US20210147432A1 (en) 2021-05-20
ES2890226T3 (es) 2022-01-18
TWI756305B (zh) 2022-03-01
US12371436B2 (en) 2025-07-29
CA3043132A1 (en) 2018-05-31
CN110214141A (zh) 2019-09-06
ZA201902710B (en) 2021-10-27
HUE055692T2 (hu) 2021-12-28
KR102517273B1 (ko) 2023-04-03
PL3544981T3 (pl) 2021-12-20
US20190315757A1 (en) 2019-10-17
TW201833111A (zh) 2018-09-16
JP2019535747A (ja) 2019-12-12
GB201619694D0 (en) 2017-01-04
MX2019005934A (es) 2019-11-12
JP6980014B2 (ja) 2021-12-15
US11739094B2 (en) 2023-08-29
EA039607B1 (ru) 2022-02-16
US20250304590A1 (en) 2025-10-02
EA201991253A1 (ru) 2019-11-29
IL266745A (en) 2019-07-31
US10941149B2 (en) 2021-03-09
AU2017364308A1 (en) 2019-05-23
PT3544981T (pt) 2021-09-23
DK3544981T3 (da) 2021-09-20
US20240067653A1 (en) 2024-02-29
BR112019009864A2 (pt) 2019-08-27
CN110214141B (zh) 2022-05-31

Similar Documents

Publication Publication Date Title
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
EP3533787A4 (en) PYRIDONE COMPOUND AS A C-MET INHIBITOR
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
EP3464275A4 (en) EGFR INHIBITOR COMPOUNDS
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
EP3558322A4 (en) ANTIVIRAL BENZYL AMINE PHOSPHODIAMIDE COMPOUNDS
EP3386981A4 (en) HETEROCYCLES SUITABLE AS ANTICROGEN
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
EP3532069A4 (en) ANTIVIRAL ARYL AMID PHOSPHODIAMID COMPOUNDS
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA52063A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma